Author Interviews, Breast Cancer, Mayo Clinic, Surgical Research, Weight Research / 02.05.2014

Tina Hieken, M.D. Associate Professor of Surgery Mayo Clinic,Rochester, MinnMedicalResearch.com Interview with: Tina Hieken, M.D. Associate Professor of Surgery Mayo Clinic,Rochester, Minn   MedicalResearch.com: What are the main findings of the study? Dr. Hieken: Among more than 1,300 newly diagnosed invasive breast cancer patients, 36 percent of whom were obese (BMI ≥ 30), preoperative axillary ultrasound with fine needle aspiration biopsy of suspicious lymph nodes identified metastasis to the lymph nodes in 36 percent of patients found to be node-positive at operation.  For all BMI categories (normal, overweight, obese) axillary ultrasound was predictive of pathologic nodal status (p<0.0001).  The sensitivity of axillary ultrasound did not differ across BMI categories while specificity and accuracy were better for overweight and obese patients, respectively, than for normal weight patients.  Furthermore, patients across all BMI categories who had suspicious axillary lymph nodes on ultrasound and had a positive fine needle aspiration biopsy had significantly more positive lymph nodes at operation, an average of five metastatic nodes, and an overall higher nodal disease burden at operation. (more…)
Author Interviews, Breast Cancer, Genetic Research / 29.04.2014

Dr. Yvonne Bombard, PhD Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital Assistant Professor, Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of TorontoMedicalResearch.com Interview with: Dr. Yvonne Bombard, PhD Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital Assistant Professor, Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto MedicalResearch.com: What are the main findings of the study? Dr. Bombard: The main finding of the study is that gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean. For many the gene expression profiling test was the main factor in their treatment decision. The women we interviewed understood the test would indicate whether chemotherapy would be beneficial to them. But many thought the test reflected their unique circumstances and did not understand that their test result was based on larger population statistics. Patients often viewed their gene expression profiling results as providing information that was more scientifically valid, uniquely personalized and emotionally significant than any other information they had received. For many, the test was a transformational element that empowered them, allowed them to feel confident in their decisions and may even have rescued them from unnecessary chemotherapy. Patients described emotionally and socially complex reasons why they valued gene expression profiling testing in making their treatment decisions. Patients valued the test because it provided them with certainty amidst confusion, with options and a sense of empowerment, and with personalized, authoritative information. (more…)
Author Interviews, Breast Cancer, JNCI, Nutrition / 11.04.2014

dr_sabina-sieriMedicalResearch.com Interview with: Sabina Sieri, PhD Epidemiology and Prevention Unit Department of Preventive & Predictive Medicine Fondazione IRCCS Istituto Nazionale dei Tumori 20133 Milan – Italy MedicalResearch.com: What are the main findings of this study? Dr. Sieri: In our study we found that there was an increased risk of developing breast cancer from high saturated fat intake. High total and saturated fat intake were associated with greater risk of ER PR positive breast cancer. High saturated fat intake was also associated with a greater risk of HER2 negative disease. So, a high-fat diet increases breast cancer risk and, most conspicuously, a high saturated fat intake increases the risk of developing hormone-sensitive diseases, suggesting saturated fat involvement in the etiology of hormone-sensitive breast cancer. (more…)
Author Interviews, Breast Cancer, Mayo Clinic / 10.04.2014

Dr. Judy C. Boughey MD Professor of Surgery Mayo Clinic, Rochester MNMedicalResearch.com Interview with Dr. Judy C. Boughey MD Professor of Surgery Mayo Clinic, Rochester MN MedicalResearch.com: What are the main findings of the study?   Dr. Boughey: This study showed that the rate of reoperation after lumpectomy for breast cancer was significantly lower at Mayo Clinic in Rochester compared to national data. Mayo Clinic in Rochester uses frozen section analysis of margins at time of lumpectomy to direct any margin re-excisions during the surgery and therefore has a significantly lower rate of need for a second operation to ensure clean margins. The rate of reoperation was four times higher in the national data set than in the Mayo Clinic data set. (more…)
Breast Cancer, JAMA, Outcomes & Safety / 03.04.2014

Dr. Lydia  Pace, MD, MPH Division of Women’s Health, Brigham and Women’s Hospital Boston, MassachusettsMedicalResearch.com Interview with: Dr. Lydia  Pace, MD, MPH Division of Women’s Health, Brigham and Women’s Hospital Boston, Massachusetts MedicalResearch.com: What are the main findings of the study? Dr. Pace: We reviewed the existing literature about the benefits and harms of mammography, focusing on the reduction of breast cancer deaths associated with mammography, as well as the two most often-discussed harms: false positive results and overdiagnosis. We also reviewed the literature about interventions to help patients make informed decisions. We found that the literature suggests that routine screening mammography does reduce mortality associated with breast cancer, across all age groups. However, it is also associated with high rates of false positive results, and considerable rates of overdiagnosis. Overdiagnosis is the most concerning potential risk of mammography screening. Overdiagnosis is the detection of a tumor through screening that would never have caused problems for a patient. It occurs either because of a very slow-growing tumor, or because a woman has medical problems (or is old enough) such that she will likely die of another cause before the cancer became apparent. Overdiagnosis is concerning because we cannot know when a cancer is overdiagnosed, and thus a patient who is overdiagnosed will receive unnecessary treatment for cancer. The scientific literature on mammography is complex, and there are important limitations to the studies both of mammography’s benefits and harms. However, we feel that the best available data suggest that among 10,000 50 year old women undergoing annual mammography for 10 years, 5 deaths will be averted through screening mammography, while about 6130 women will experience at least one positive result. Furthermore, there is about a 19% chance that, if that woman is diagnosed with cancer detected by a mammogram, that cancer is one that would never have caused her problems. Lastly, our review showed that we need more studies to guide us in how an individual woman’s risk should dictate her mammography decisions, and how to support women in making those decisions. However, we know that most women with higher risk for breast cancer will experience higher benefit from mammography screening. (more…)
Aging, Author Interviews, Breast Cancer, Chemotherapy, JNCI / 30.03.2014

Hanna Sanoff MD, MPH Lineberger Comprehensive Cancer Center Department of Medicine University of North Carolina, Chapel Hill, NCMedicalResearch.com Interview with: Hanna Sanoff MD, MPH Lineberger Comprehensive Cancer Center Department of Medicine University of North Carolina, Chapel Hill, NC MedicalResearch.com: What are the main findings of the study? Dr. Sanoff: We measured p16, a protein that increases with cellular aging, in blood cells of women receiving chemotherapy for breast cancer. We found that a standard course of chemotherapy led to an increase in p16 expression equivalent to what we have previous seen in people over the course of 10-15 years of chronological aging. This increase persisted in cancer survivors an average of three and half years after treatment. (more…)
Author Interviews, Breast Cancer, Cancer, NIH / 26.03.2014

Yun Gong, M.D. Associate Professor Department of Pathology, Unit 53 M D Anderson Cancer Center Houston, TX 77030MedicalResearch.com Interview with: Yun Gong, M.D. Associate Professor Department of Pathology, Unit 53 M D Anderson Cancer Center Houston, TX 77030 MedicalResearch.com: What are the main findings of the study? Dr. Gong:  Androgen receptor (AR) was positive in 39% of the inflammatory breast cancer (IBC) tumors, approximately one-third of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumors and 42.6% triple-negative tumors. AR positivity was significantly associated with lymphovascular invasion but not with other clinicopathologic parameters. There was a trend toward association between AR expression and PR expression. Univariate survival analysis indicated that patients with AR-negative/ER-negative tumors had significantly worse overall survival and disease-specific survival than the patients with tumors showing other combinations of AR/ER status (i.e., AR-negative/ER-positive, AR-positive/ER-negative,  or AR-positive/ER-positive). Notably, the study was performed using post-neoadjuvant IBC surgical specimens. (more…)
Breast Cancer, Exercise - Fitness / 20.03.2014

Professor Mathieu Boniol PhD International Prevention Research Institute Lyon, FranceMedicalResearch.com Interview with: Professor Mathieu Boniol PhD International Prevention Research Institute Lyon, France MedicalResearch.com: What are the main findings of the study? Prof. Boniol: We conducted a meta-analysis of all prospective epidemiological studies on physical activity and risk of breast cancer. It includes 37 studies, so covers more than 4 million women among which more than 100,000 breast cancer were diagnosed. We showed that when comparing the most active women (about 20% of the population) to least active women (another 20% of the population), vigorous physical activity reduce the risk of breast cancer by 11%. And the good news is that this decline is irrespective of age, BMI, menopausal status, country,... It is also true for the most aggressive breast cancer (ER-/PR-). However, we also showed that this decline is not observed for women taking hormonal replacement therapies, as if these treatments (which are already infamous for poor efficacy and increasing the risk of breast cancer) would nullify any benefit from physical activity. (more…)
Author Interviews, Breast Cancer, PLoS / 22.02.2014

Bodour Salhia, PhD Assistant Professor Integrated Cancer Genomics Division Translational Genomics Research Institute Phoenix, Arizona, 85004MedicalResearch.com Interview with: Bodour Salhia, PhD Assistant Professor Integrated Cancer Genomics Division Translational Genomics Research Institute Phoenix, Arizona, 85004 MedicalResearch.com: What are the main findings of the study? Dr. Salhia: Our study identified novel rare genomic and epigenomic events underlying breast cancer metastasis to brain. We demonstrated that we could molecularly subtype breast cancer brain metastasis the same way we can subtype primary breast cancer. From this analysis we found that the Luminal B subtype was the most common subtype in our cohort, followed by Her2+/ER- enriched tumors and Basal-like tumors. Each of these subtypes displayed genetic and epigenetic features reminiscent of primary breast cancer. We demonstrated that these tumors have a strong predilection to grow by activating pathways involved in G2/M cell cycle progression, whereas, many genes involved in cell migration were epigenetically silenced. Broad amplification of chromosome 8q was common, which resulted in the upregulation of important genes. (more…)
Author Interviews, BMJ, Breast Cancer, Mammograms / 13.02.2014

Anthony Miller, MD Director, Canadian National Breast Screening Study Professor Emeritus, Dalla Lana School of Public Health University of TorontoMedicalResearch.com Interview with: Anthony Miller, MD Director, Canadian National Breast Screening Study Professor Emeritus, Dalla Lana School of Public Health University of Toronto MedicalResearch.com: What are the main findings of the study? Prof. Miller:  The study involved 89,835 women aged 40 to 59. All underwent an annual physical breast examination, while half were randomly assigned to undergo annual mammograms for five years, beginning in 1980. During the five-year screening period, 666 invasive breast cancers were diagnosed in the mammography arm and 524 in the controls.  Over the 25 year follow-up 180 women in the mammography arm and 171 women in the control arm died of breast cancer.  The overall hazard ratio for death from breast cancer diagnosed during the screening period associated with mammography was 1.05 (95% CI: 0.85 – 1.30).  The findings for women aged 40-49 and aged 50-59 were almost identical. After 15 years of follow-up an excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis, i.e. 22% of screen-detected invasive breast cancers, half of those detected by mammography alone. This represents one over-diagnosed breast cancer for every 424 women screened by mammography. By 2005, 3,250 of the 44,925 women in the mammography arm of the study were diagnosed with breast cancer, and 500 had died of it. The control group of 44,910 women had 3,133 breast cancer diagnoses and 505 breast cancer deaths. We conclude that annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available. (more…)
Author Interviews, Breast Cancer, Journal Clinical Oncology, Radiation Therapy, Sloan Kettering, Surgical Research / 12.02.2014

dr_monica_morrow MedicalResearch.com Interview Invitation with: Monica Morrow MD Anne Burnett Windfohr Chair of Clinical Oncology Chief Breast Service memorial Sloan Kettering Cancer Center MedicalResearch.com: What are the main findings of the study? Dr. Morrow: The study is the report of a Consensus panel examining the question of whether more widely clear lumpectomy margins than no ink on tumor decrease local recurrence.  A metaanalysis of published literature was used as the primary evidence base for the conclusion. (more…)
Author Interviews, Breast Cancer, Cancer, Smoking / 12.02.2014

MedicalResearch.com Interview with: Masaaki Kawai MD, PhD Division of Public Health Sciences, Fred Hutchinson Cancer Research Center Seattle, Washington MedicalResearch.com:  What are the main findings of the study? Answer:  Ever-smokers had a 1.3-fold increased risk of breast cancer. They also had a 1.4-fold increased risk of ER-positive breast cancer. Current/recent smokers with a 10 pack-year history of smoking had a 1.6-fold increased risk of ER-positive breast cancer. (more…)
Author Interviews, Breast Cancer, Dartmouth, Radiology / 27.01.2014

Michael Mastanduno Thayer School of Engineering, Dartmouth College 14 Engineering Dr. Hanover, NH 03755MedicalResearch.com Interview with: Michael Mastanduno Thayer School of Engineering, Dartmouth College 14 Engineering Dr. Hanover, NH 03755 MedicalResearch.com: What are the main findings of the study? Answer: The study was able to illustrate the design and clinical testing of an MRI breast coil for combined MRI and Near Infrared Spectroscopy. The coil was tested on 8 healthy volunteers spanning all bra cup sizes and mammographic density categories. In the past, MRI/NIRS imaging was only possible in C and D cup sized breasts. The system also will give researchers the ability to target lesions in hard-to-reach areas close to the chest wall. With the successful completion of this study, simultaneous MRI/NIRS is possible in all breast sizes, tissue compositions, and lesion locations. (more…)
Author Interviews, Breast Cancer / 26.01.2014

MedicalResearch.com Interview with: Deirdre McLaughlin PhD MAPS Associate Professor, Principal Research Fellow Centre for Longitudinal and Lifecourse Research and Janni Leung, BHS School of Population Health University of Queensland MedicalResearch.com: What are the main findings of the study? Answer: Breast cancer patients living in rural areas were diagnosed later than breast cancer patients living in urban areas. Evidence from Australia, Egypt, Italy, Canada, Poland, South Africa, Denmark, and parts of the United States indicated that patients residing in rural areas were more likely to be diagnosed with more advanced breast cancer. Our meta-analysis showed that rural breast cancer patients had 1.19 higher odds (95% confidence interval= 1.12-1.27) of diagnosis of a late stage breast cancer compared to urban breast cancer patients. (more…)
Author Interviews, Breast Cancer, Psychological Science, Radiation Therapy / 22.01.2014

Guy H. Montgomery, Ph.D. Director, Integrative Behavioral Medicine Program Cancer Prevention and Control Department of Oncological Sciences, Box 1130 Icahn School of Medicine at Mount Sinai New York, NY 10029-6574MedicalResearch.com Interview with: Guy H. Montgomery, Ph.D. Director, Integrative Behavioral Medicine Program Cancer Prevention and Control Department of Oncological Sciences Icahn School of Medicine at Mount Sinai New York, NY 10029-6574 MedicalResearch.com: What are the main findings of the study? Dr. Montgomery: A brief psychological intervention comprised of cognitive behavioral techniques and hypnosis (CBTH) reduced fatigue during, and for up to six months after, radiotherapy in breast cancer patients. (more…)
Author Interviews, Breast Cancer, Surgical Research / 17.01.2014

MedicalResearch.com Interview with: Dr. R.A. Badwe, MS Director,  Tata Memorial Centre E. Borges Marg, Parel Mumbai 400 012 MedicalResearch.com: What are the main findings of the study? Answer: The trial was a randomized control study involving 350 women with per primum metastatic breast cancer. These women were divided into two groups from February 2005 to May 2013. One group underwent surgery and radiotherapy (LRT) (n=173) while another group of 177 women were spared these (no LRT). Both groups had undergone six successful rounds of chemotherapy before their recruitment into the trial. Women who underwent surgery had the primary breast tumour and lymph nodes removed, followed by locoregional radiation therapy. The primary endpoint of the study was overall survival (OS). At a median follow-up of 17 months, no difference was observed in OS between the groups; the OS rates were 19.2% and 20.5%, respectively, (HR = 1.04; 95%CI, 0.80-1.34; P = 0.79).  The lack of a survival benefit is due to a trade-off between local control and distant disease progression. The results indicated that women who underwent surgery and had improved locoregional control and significantly worse distant progression-free survival compared with women who did not undergo surgery (HR = 1.41; 95% CI, 1.08-1.85; P = .01). Progression of distant disease was 42% more likely (P = .01) in the LRT arm whereas the risk of local progression was 84% lower with LRT. (more…)
Author Interviews, Breast Cancer, Nutrition / 21.12.2013

Adana A.M. Llanos, PhD, MPH Assistant Professor, Department of Epidemiology RBHS-School of Public Health Rutgers, The State University of New Jersey Piscataway, NJ 08854MedicalResearch.com Interview with: Adana A.M. Llanos, PhD, MPH Assistant Professor, Department of Epidemiology RBHS-School of Public Health Rutgers, The State University of New Jersey Piscataway, NJ 08854 MedicalResearch.com: What are the main findings of the study? Dr. Llanos: Our longitudinal study examined the effects of both tomato-rich and soy-rich diets in a group of 70 postmenopausal women who participated in the study at The Ohio State University Comprehensive Cancer Center. For 10 weeks, women ate tomato products containing at least 25 milligrams of lycopene daily. For a separate 10-week period, the participants consumed at least 40 grams of soy protein daily. Before each test period began, the women were instructed to abstain from eating both tomato and soy products for two weeks. We examined the dietary intervention effects on hormone biomarkers known to be associated with obesity, namely adiponectin and leptin. After the tomato-rich diet participants' levels of adiponectin climbed nine percent. The effect was slightly stronger in women who had a lower body mass index. (more…)
Author Interviews, Breast Cancer, Chemotherapy / 20.12.2013

MedicalResearch.com Interview with: Prof. Dr. med. Sibylle Loibl MD Unit Head of Medicine & Research Member of Management Board Associate Professor University Frankfurt GBG Forschungs GmbH
 Neu-Isenburg MedicalResearch.com: What are the main findings of the study? Dr. Loibl: We could demonstrate that patients with a HER2+ primary breast cancer harbouring a PIK3CA mutation are less likely to achieve a pathological complete response after treatment with an anthracycline/taxane containing therapy in combination with trastuzumab and lapatinib, than patients whose tumours does not harbour the mutation (so called wild type). This difference was largest in the group with HER2+, HR + tumours. The pCR rate in this cohort was as low as 6.3%. Looking at the differences in another study with either trastuzumab or lapatinib anti-HER2 treatment is seems as patients with a PIK3CA mutated tumour have a low pCR rate irrespective of the antiHER2 treatment, whereas the patients with a wild type tumour benefit from trastuzumab and the double blockade. (more…)
Author Interviews, Breast Cancer, Radiology / 06.12.2013

Nicholas M Perry MD London Breast InstituteMedicalResearch.com Interview with: Nicholas M Perry MD London Breast Institute MedicalResearch.com: What are the main findings of your study? Dr. Perry: The main findings from the study were that automated density readings outperformed radiologists, and that women under the age of 50 had a more significant risk of breast cancer from higher breast density. Also, and quite surprising was the appearance of a completely different age- density pattern in women with breast cancer. Whereas the women in the study without cancer showed a normal and steady decline in breast density with age, those with cancer showed a completely different curvi-linear pattern, which was evident in women as young as 30. The message is that breast density remains an important factor for both the current breast screening methodologies, and for future research into investigation and management. (more…)
Author Interviews, Breast Cancer, Nutrition, Pediatrics, University of Michigan / 01.12.2013

Richard Schwartz, Ph.D. Professor, Associate Dean for Graduate Academic and Student Affairs College of Natural Science Michigan State University Department of Microbiology and Molecular Genetics Michigan State University East Lansing, MI 48824-4320MedicalResearch.com Interview with: Richard Schwartz, Ph.D. Professor, Associate Dean for Graduate Academic and Student Affairs College of Natural Science Michigan State University Department of Microbiology and Molecular Genetics Michigan State University East Lansing, MI 48824-4320 MedicalResearch.com: What are the main findings of the study? Dr. Schwartz: The main finding is that exposure to a high fat diet from the age of puberty onwards hastened the development of chemical carcinogen-induced breast cancer in absence of weight gain. We also found that prior to the appearance of any tumors, we could detect changes in the mammary gland that included increased cellular proliferation, increased vascularity, and changes in immune function. (more…)
Author Interviews, Breast Cancer, Chemotherapy, Lancet, MD Anderson / 24.11.2013

Dr. Kelly K. Hunt, M.D., F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology The University of Texas MD Anderson Cancer Center, Houston, TXMedicalResearch.com Interview with: Dr. Kelly K. Hunt, M.D., F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology The University of Texas MD Anderson Cancer Center, Houston, TX MedicalResearch.com: What are the main findings of the study? Dr. Hunt: The primary endpoint of the Z1041 trial was the proportion of patients who had pathological complete response in the breast, defined as the percentage of women who started the neoadjuvant treatment with no histological evidence of disease in the breast at surgery.  We found that high pathologic response rates were observed in both treatment groups with similar cardiac safety profiles in both arms of the trial.  Specifically, 56.5% of patients in the sequential group (fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle for four cycles followed by paclitaxel plus trastuzumab weekly for 12 weeks) had a complete pathological response versus 54.2% of the patients who received the concurrent regimen (paclitaxel and trastuzumab weekly for 12 weeks followed by fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle with trastuzumab on days one, eight and 15 of the 21-day cycle for four cycles).  The difference in pathologic complete response rates between the treatment arms was not statistically significant.  Cardiac safety was a secondary endpoint of the trial and we found that both regimens had acceptable cardiac safety profiles. (more…)
Author Interviews, Breast Cancer, Lancet, Radiation Therapy / 11.11.2013

Prof Jayant S Vaidya PhD Clinical Trials Group, Division of Surgery and Interventional Science University College London, London, UKMedicalResearch.com Interview with: Prof Jayant S Vaidya PhD Clinical Trials Group, Division of Surgery and Interventional Science University College London, London, UK MedicalResearch.com: What are the main findings of the study? Dr. Vaidya: The main findings are
  • a) these are longer term results that have confirmed our original publication in 201
  • (b) We found that when TARGIT intraoperative radiotherapy is given at the time of lumpectomy for breast cancer, the local control and survival from breast cancer is similar to several weeks of whole breast radiotherapy
  • c) we also found that with TARGIT there are significantly fewer deaths from other causes - i.e., fewer deaths from cardiovascular causes and other cancers
(more…)
Author Interviews, Breast Cancer / 07.11.2013

Mila Donker, MD Resident in Radiation Oncology Study monitor EORTC 10981-22023 AMAROS trialMedicalResearch.com Interview with: Mila Donker, MD Resident in Radiation Oncology Study monitor EORTC 10981-22023 AMAROS trial The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands MedicalResearch.com: What are the main findings of the study?  Dr. Donker: Results of EORTC trial 10853 which were recently published in the Journal of Clinical Oncology showed that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). Between 1986 and 1996, this phase III EORTC trial 10853 randomized 1010 women with complete local excision of DCIS to no further treatment (503 patients) or radiotherapy (507 patients). The risk of any local recurrence was found to be reduced by 48% in the patients who also received radiotherapy. The 15-year local recurrence-free rate was 69% for the group of patients receiving breast conserving surgery alone, but this increased to 82% for the group of patients who also received radiotherapy, and the 15-year invasive local recurrence-free rate was 84% versus 90%, respectively. (more…)
Author Interviews, Breast Cancer / 11.10.2013

Dr. S. Wassertheil-Smoller PhD Distinguished University Professor Emerita Department of Epidemiology & Population Health Principal Investigator, Women's Health Initiative Albert Einstein College of Medicine | 1300 Morris Park Avenue Bronx, NY 10461MedicalResearch.com Interview with: Dr. S. Wassertheil-Smoller PhD Distinguished University Professor Emerita Department of Epidemiology & Population Health Principal Investigator, Women's Health Initiative Albert Einstein College of Medicine | 1300 Morris Park Avenue Bronx, NY 10461 MedicalResearch.com: What are the main findings of the study? Answer: We studied 7728 older women who developed invasive breast cancer during their participation in the Women’s Health Initiative, known as WHI. This study found that women with invasive breast cancer who are users of multivitamin and mineral supplements had a 30% lower risk of dying from their breast cancer compared to non-users. This protective effect was observed to be independent of a large number of factors which affect breast cancer outcomes and which account for differences between users and non-users. The women we studied were ages 50-79 when they started the WHI. (more…)
Author Interviews, Breast Cancer, Chemotherapy, MD Anderson, Vanderbilt / 10.10.2013

MedicalResearch.com Interview with: Hiroko Masuda MD

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic; Departments of 2Breast Medical Oncology, 3Bioinformatics and Computational Biology The University of Texas MD Anderson Cancer Center, Houston, Texas;

W. Fraser Symmans, MD Anderson Cancer Center, Department of Pathology, Unit 85, 1515 Holcombe Blvd., Houston, TX 77030-4009;

Naoto T. Ueno, MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030.

MedicalResearch.com: What are the main findings of the study?

Answer: Triple-negative breast cancer (TNBC) could be classified into 7 subtypes: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M),mesenchymal stem-like (MSL), luminal androgen receptor (LAR), and unstable (UNS). Using cluster analysis, Lehmann and Bauer et al. identified these TNBC subtypes in 21 public mRNA gene expression profiles of breast cancer. However, the clinical relevancy of these novel molecular subtypes has not been established. To establish the clinical relevancy, we determined if the subtypes of TNBC have different rates of pathological complete response (pCR) to standard neoadjuvant chemotherapy regimens. In this study, we confirmed that TNBC is heterogeneous and that pCR differs by TNBC subtype using the algorithm proposed by Lehmann and Bauer et al. The BL1 subtype had the highest pCR rate (52%), and BL2 and LAR had the lowest pCR rates (0% and 10%, respectively). TNBC subtype was an independent predictor of pCR status (P=0.022) via a likelihood ratio test. To our knowledge, this was the first study to show that the TNBC subtype can serve as an independent predictor of pCR status in patients who received standard chemotherapy regimens. This confirms the possible clinical relevance of the 7 molecular subtypes, and these subtypes may lead to innovative clinical trials of personalized medicine for patients with TNBC. (more…)

Author Interviews, Breast Cancer, JAMA, MD Anderson / 08.10.2013

Kelly K. Hunt, MD F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXMedicalResearch.com Interview with: Kelly K. Hunt, MD F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX MedicalResearch.com: What are the main findings of the study? Dr. Hunt: We found that 40% of women who had node positive disease at initial presentation (confirmed by needle biopsy) had no evidence of residual cancer in the lymph nodes after chemotherapy. We performed sentinel lymph node (SLN) surgery followed by axillary lymph node dissection in all of the patients and found a false negative rate of 12.6% with the SLN procedure. The false negative rate was lower when surgeons used two mapping agents (blue dye and radioisotope) to identify the sentinel nodes and when they removed more than 2 sentinel nodes. (more…)
Author Interviews, Breast Cancer, Cancer Research, Lancet / 20.09.2013

Prof Aron Goldhirsch Department of Medicine European Institute of Oncology Via Ripamonti 435, 20141 Milan, ItalyMedicalResearch.com Interview with: Prof Aron Goldhirsch Department of Medicine European Institute of Oncology Via Ripamonti 435, 20141 Milan, Italy MedicalResearch.com: What are the main findings of the study? Prof. Goldhirsch:  Two years of adjuvant trastuzumab after standard chemotherapy is not more effective than is 1 year of treatment with the drug for patients with HER2-positive early breast cancer. (more…)
Author Interviews, Breast Cancer, Lancet / 20.09.2013

Prof John R Yarnold Division of Radiotherapy and Imaging The Royal Marsden NHS Foundation Trust Sutton, Surrey SM2 5PT, UKMedicalResearch.com Interview with: Prof John R Yarnold Division of Radiotherapy and Imaging The Royal Marsden NHS Foundation Trust Sutton, Surrey SM2 5PT, UK   MedicalResearch.com: What are the main findings of the study? Prof. Yarnold: A 3-week schedule of curative post-operative radiotherapy for women with breast cancer involving 15 treatments (fractions) delivered Monday to Friday each week, is at least as safe and effective as historical schedules given over 5 or 6 weeks. In fact the 3-week schedule is gentler on the healthy tissues than earlier standard regimens. (more…)
Author Interviews, Breast Cancer, MRI / 13.09.2013

Nariya Cho, MD Departments of Radiology Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.MedicalResearch.com Interview with: Nariya Cho, MD Departments of Radiology Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.   MedicalResearch.com: What are the main findings of the study? Dr. Cho: Smaller reduction in tumor volume and a smaller reduction in washout component on dynamic contrast agent–enhanced MR imaging assessed by computer-aided evaluation after neoadjuvant chemotherapy were independent parameters of worse recurrence-free survival and overall survival in breast cancer patients who received neoadjuvant chemotherapy. (more…)
Alcohol, Author Interviews, Breast Cancer, JNCI, OBGYNE / 30.08.2013

MedicalResearch.com Interview with: Ying Liu, MD, PhD Instructor, Division of Public Health Sciences Department of Surgery Washington University School of Medicine 660 South Euclid Ave Campus Box 8100 St. Louis, MO 63110 MedicalResearch.com: What are the main findings of the study? Answer: Alcohol intake between menarche (first menstrual period) and first pregnancy was consistently associated with increased risks of breast cancer and proliferative benign breast disease. For every 10 gram/day alcohol intake (approximately a drink a day) during this specific time period, the risk for breast cancer increased by 11% and the risk for proliferative benign breast disease increased by 16%. (more…)